synuclein gene, mutation of PARKIN gene, PINK-1 gene, and DJ-1 gene [8] . The mutation in these genes can lead to abnormal folding of protein and dysfunction of mitochondrial [3] . The possible environmental factors are like pesticides, herbicides and drinking well water [10] . Any combination of these factors could contribute to the development of PD by causing or accelerating nitrostriatal cell death.
Current options for the treatment of PD are either medical or surgical. approach. Different drug therapies are available for PD treatment. These drugs are used in combination as there is still no single effective treatment for PD. Examples of drugs available are levodopa, dopamine agonist, and selegiline. The aim of using the levodopa is to resupply the dopamine in the substantia nigra. Even though Levodopa is an effective drug in PD treatment, it is usually used in older patients, always advised to start at a lower dose, and used in patients with moderate to severe motor disability. There is no "Gold Standard" treatment for PD as yet and the choice of treatment usually is based on the patient's symptoms.
The limitation with the medication is that the patients will eventually face more fluctuation in motor symptoms and start to experience dyskinesia [11] . The motor fluctuation is described as "on" and "off " state. "ON" refers to improvement in the 'wearing off ' symptoms after taking the treatment especially seen with Levodopa, and "OFF" refers to worsening of the PD symptoms before time for taking next dose of medication [12] . Dyskinesia refers to involuntary "wriggling" movement which usually occurs when a patient is in "ON" state. Once medical treatments are no longer effective, patients might have to consider surgical options like pallidotomy and deep brain stimulation [11] .
Currently, stem cell therapy for PD is still under experimental stage, most of the studies were done in animals. The first clinical trial on PD patient was reported in 1989 by using aborted human fetal ventral midbrain tissue [13] . Since then, different clinical trials were conducted at different centers, using different sources of stem cells. However, the results produced were inconsistent, even for those patients treated in the same center and in the same study. Some of the results were promising and some didn't show any improvement. This review is conducted in order to assess the potential use and safety profile of stem cell therapy in PD. If the clinical efficacy could be established, it could serve as an initial step for more future clinical trials.
THE CLINICAL POTENCY AND SAFETY OF STEM CELL IN TREATING PARKINSON'S DISEASE
To determine the clinical potency and safety of stem cell in treating PD, a comprehensive analysis of reported clinical trials was conducted. A comprehensive search using the PubMed, Cochrane's Library, and Google Scholar was conducted in the English language from year 2000 to 2015. The keywords used were stem cell, embryonic stem cell, pluripotent stem cell, cell, Parkinson's disease, transplant and implant. The methodology employed in selecting clinical trials reported in journal articles and the quality assessment using JADAD score is described in details in Supplementary Material (in the online-only Data Supplement).
A total of 11 articles were included for analysis, with four randomised control trial (RCT), five non-RCT and 2 follow up studies. Periodic report summary from one ongoing multicenter open label clinical grafting trial sponsored by the European Union (TRANSEURO) was reviewed but has not been included in this study since details of patients and treatment protocol are not included in the report. The comparison of the results and side effects of the studies are presented in Table  1-7. A total of 243 participants were included in these 11 selected studies with breakdown of 183 participants in RCT and 60 in non-RCT (Table 1) . Different type of cells was either unilateral or bilateral were transplanted in PD patients via surgery (Table  2) . In RCT studies, except study by Olanow et al. [14] , which used placebo in control group, sham surgery was done in control group (Table 1) . In both RCT and non-RCT studies the duration of follow up after transplant was between 12 to 36 months. Nine patients in follow up studies were monitored for the improvement as well as for any potential side effects between 5 to 18 years after transplant.
Four non-RCT showed improvement of Unified Parkinson's Disease Rating Scale (UPDRS) with no adverse events. Study by Xue et al. [15] shown the contralateral symptom improvement in 7 days, 1 month, and 3 months after transplantation. The ipsilateral symptom improvement was evaluated at 1 month and 3 months after transplantation.
Except studies by Trott et al. [16] in the other studies the primary end point was change between baseline and final visits in motor component of the Unified UPDRS in the practically defined off state (Table 3 , 4, and 5). Trrot et al. [16] used neuropsychological tests to assess orientation, attention, language, verbal and visual memory, abstract reasoning, executive function, and visuospatial and construction abilities before and 1 year after surgery (Table 6) .
In three RCT studies details of side effects were reported. The reported side effects were included death, dyskinesia, subdural hematoma, depression, hallucinations and falls (Table 7) . There was no report of any serious adverse events in rest of studies. [16] were actually done on the same patients, but different outcomes were measured in the studies. The major improvement in PD patients was measured by Unified UPDRS, in both "on" and "off " state.
The main difference between the RCTs and non-RCTs is that they produced opposite results. When the studies were performed as non-RCTs in small number of patients, they showed promising result in the patients. Stover et al. [18] did a clinical study on 6 PD patients. The mean duration of PD in these patients was 10.2 years. In his study, human RPE attached to microcarrier was used. At 12th month follow up, he showed a 42% improvement in UPDRS score in "off " state. But this is a not significant result as the p value was 0.3. Venkataramana et al. [19] had conducted two different clinical studies. They first conducted a study on seven patients using the method of unilateral implantation of BM-MSC, at 12th month follow up, the improvement in UPDRS score during "off " state was 33% and during "on" state was 28%. They then conducted another clinical trial in 12 patients by doing bilateral transplantation of BM-MSC. This study also showed improvement in UPDRS score at 12 months in both "off " and "on" state [20] .
Another clinical study was conducted by Yin et al. [21] using human RPE. This study was carried out in eleven patients, which managed to showed a significant increase of 34% (p value=0.006) in UPDRS score during "on" state at 12th month follow up. The positive finding in these non-RCTs could be due to the small number of patients involved in the study, as well as bias by the investigator and patient.
Gross et al. [22] conducted a double blinded RCT on 71 patients using human RPE bound to microcarrier. The mean age Table 5 . Changes in UPDSRS score seen in study by Olanow et al. [22] No. Author Title Table 6 . Neuropsychological test (means and SD) for all patients in each treatment group at baseline and at one year follow up [14] Test NA: no available data/or not mentioned in study, T: transplant group, C: control group of patients in his study was 55.9 years old. The follow up at 12 months post implantation showed slight improvement in UP-DRS score during "off " state. When compared to the control group, which was Sham surgery, both procedures showed no significant difference in the scores of UPDRS. Freed et al. [17] used embryonic dopamine neurons in the RCT. In this study, patients were randomly divided into two groups, one with bilateral implantation of embryonic dopamine neurons, and another group with Sham surgery. At 12th month follow up, the study failed to show any improvement in implant group, and there is no difference with the clinical outcome in those patients who had Sham surgery. However, secondary analysis of the study showed younger patients (60 years old and younger) had a significant improvement in UPDRS score (p=0.01), and the improvement in striatal 18F-fluorodopa uptake was confirmed by PET scan [17] . This showed that may be the brain plasticity of a younger patient is better. The neurological assessment carried out by Trott et al. [16] showed that there was no neurologic and cognitive improvement in the treatment group when assessed at 12th month.
In the RCT conducted by Olanow et al. [14] , they divided 34 patients into three groups. One was Sham surgery as control, and the other two groups were given two different doses of fetal tissue (with one donor and four donors). The patients in this study were followed up and assessed. The assessment at 24 months failed to show any improvement in the motor symptoms by UPDRS score, regardless of the dosage of tissue used.
All the non-RCTs reported no significant side effects associated with the treatment. However, in the RCTs, it showed that the total percentage of side effects was higher in the transplant group when compared to Sham surgery group. The incidence of serious side effects was also seen with the transplant group, as showed in Table 7 . One of the common complications of PD is dyskinesia; it had a higher incidence with the transplant group as shown in Table 7 . This could be due to the extensive fiber outgrowth from the transplant, which leads to an excessive dopamine level [17, 23] .
In all the RCTs, even though patients had reported some mild improvement in the initial stage of treatment [19, 20, 22] , none of these patients showed continuous improvement. In fact, deterioration of the symptoms was seen in some patients. Studies have shown that implanted stem cells are able to survive and reinnervate the striatum [23] , however it has been proven that the grafted cells can developed PD-like pathology [24] . The great difference in the findings of non-RCTs and RCTs showed the importance of a proper double blinded RCT. So far there is still no proven RCT to support the use of stem cell in PD even though non RCTs support the use. 
FUTURE PERSPECTIVES
In order to develop effective and efficient therapeutic strategies to cure neurodegenerative diseases like PD, having sourcing the therapeutic cellular resources and transplantation strategies are two major scopes of the cell therapy which are needed more attention (Fig. 1) . Autologous and allogenic cellular resources such as mesenchymal stem cells, embryo/fetus derived progenitors/stem cells possess both advantages and challenges in their utilization for cell replacement therapy. Current research interest is focused on deriving these cellular resources and expand them in vitro culture in order to generate required cell mass for transplantation. Studies also address the strategies to characterize and differentiate these cells, if it required, to produce functional cells to restore the function and activity of the organ [25, 26] . In general, the cell therapy is speculated to achieve the goal via 3 modes of therapeutic mechanisms: 1) Replacement of functional tissue/cells, 2) paracrine effect by producing neuro-protective and neuro-regenerative inducing factors, 3) anti-inflammatory effect of MSCs to protect the damage area from further undergoing neurodegeneration (Fig. 1) . Emergence of cell-based therapies is needed to be coupled with therapeutic strategies in order to establish a defined and effective cell therapeutic procedure.
CONCLUSION
Based on the results and discussion, the use of stem cell in treating PD is requires a better insight in terms of their therapeutic contribution either through tissue replacement or paracrine effect. Even though implantation of stem cell is proven to be able to survive, the survival of implanted dopamine neurons in the striatum does not indicate a success in correcting PD symptoms. The role of dopamine neurons and the neurologic innervation in PD appear to be complex. Therefore, future studies are required to make the application of stem cell in this disease practical. Meanwhile, public education, strict rules and regulation should be available to protect the patients from being harmed.
Supplementary Materials
The online-only Data Supplement is available with this article at http://dx.doi.org/10.1007/s13770-016-9093-2.
